Tag Archives: PASI

October, 2018

October, 2017

  • 27 October

    AbbVie’s Risankizumab Beats Humira and Stelara in Late-Stage Psoriasis Studies

    NORTH CHICAGO, Ill., Oct. 26, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase 3 clinical trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, compared to ustekinumab and adalimumab for the treatment of patients with moderate to severe chronic plaque …

September, 2017

October, 2015